Glaukos Ansoff Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Growth Paths Behind the Analysis
This Glaukos Amsoff Matrix Analysis gives you a clear, structured view of the company's growth options across market penetration, market development, product development, and diversification. This page already shows a real preview of the analysis, so you can review the actual content and style before buying. Purchase the full version to get the complete ready-to-use report instantly.
Market Penetration
Scale the 3-product iStent family
Glaukos Corporation is using the 3-product iStent family, iStent, iStent inject W, and iStent infinite, to take more share in established glaucoma surgery.
In FY2025, this is classic market penetration: a familiar implant-based workflow inside the same cataract and glaucoma channels, not a new disease market.
By deepening surgeon preference for the 3-product iStent franchise, Glaukos Corporation can win more cases from current accounts and lift procedure volume.
Expand iDose TR's 36-month value
iDose TR gives Glaukos Corporation a clear edge over daily eye-drop therapy by offering up to 36 months of continuous travoprost delivery. That long duration shifts the message to durability and adherence, which matters because glaucoma treatment often fails when patients miss drops. The main growth levers are physician education, correct coding, and payer access, especially in the chronic patient pool already seen by the same doctors.
Sell into 1-step cataract workflows
Glaukos Corporation gains share when surgeons can place a MIGS implant during a standard cataract case. U.S. cataract volume tops 4 million surgeries a year, so a one-step add-on fits a huge existing workflow and avoids a bigger OR change.
That makes the product easier to use, repeat, and bill, which supports adoption. In procedure markets, convenience can matter as much as efficacy when the clinical case is credible.
Cross-sell across 2 glaucoma franchises
Glaukos now has both a surgical-device franchise and a sustained-drug-delivery franchise in glaucoma, so it can sell into the same clinics, ambulatory surgery centers, and physician networks more than once. That widens account penetration because one customer can adopt more than one Glaukos solution, not just one procedure. It also raises commercial leverage: the same sales force can cover more of the glaucoma stack, which can improve revenue per account and lower selling cost per product.
Use evidence to lower reimbursement friction
In 2024-2026, access still gates ophthalmic adoption, so Glaukos Corporation can win more share by proving outcomes in real-world use, backing coding, and cutting payer doubt around new care paths. In fiscal 2025, that matters even more for a procedure-led model: faster coverage can turn trial into volume, while weak reimbursement can stall adoption. Better evidence lowers friction and makes current-market share easier to defend and expand.
Glaukos Targets Bigger Share in Cataract and Glaucoma Cases
In FY2025, Glaukos Corporation's market penetration strategy is to win more cases in the same glaucoma and cataract channels with iStent, iStent inject W, and iStent infinite. More than 4 million U.S. cataract surgeries a year give the 1-step MIGS add-on a large repeatable base, while iDose TR extends treatment for up to 36 months.
| Driver | Fact |
|---|---|
| Cataract base | 4m+ U.S. cases |
| iDose TR | Up to 36 months |
| FY2025 | Same-channel share gain |
What is included in the product
Detailed Word Document
Editable Excel File
Market Development
Extend existing products into ex-U.S. markets
In 2025, Glaukos can grow by taking its proven MIGS and corneal products into Europe and other ex-U.S. markets where adoption is still early. This is market development because the core technology stays the same while the customer base expands. It also cuts exposure to one reimbursement system and one regulator, which matters when U.S. pricing pressure stays high.
Reach 2nd-line glaucoma patients
Glaukos Corporation can expand by targeting 2nd-line glaucoma patients: people who have moved beyond first-line drops but do not yet need major incisional surgery. That pool is large, with glaucoma affecting more than 3 million Americans and many more globally, so the gap between medication-only care and surgery is still wide. In 2025, the play is to grow use of minimally invasive and drug-based options in this underserved middle stage of care.
Move from academic centers to community sites
Glaukos Corporation's move from academic centers to community ophthalmology practices and ambulatory surgery centers is a clean market-development play: the product stays the same, but the buyer base widens. That matters because MIGS and iDose TR can shift from tertiary-center use to routine, everyday care, and broader site coverage usually supports steadier procedure volume. In Glaukos Corporation's 2025 base, the key win is access, not redesign, so each new community site can add repeatable demand.
Broaden corneal care beyond glaucoma specialists
Glaukos Corporation can broaden corneal care beyond glaucoma specialists by selling its corneal-health platform to refractive and cornea specialists, a related physician group that already treats similar patients. In 2025, this matters because the U.S. cornea and refractive care base is large, and even a modest share shift can lift demand without a new product launch. The same ophthalmology-trained sales force can cover this audience, so Glaukos Corporation can expand reach while keeping the clinical message focused.
Ride 2025-2026 procedure growth
Glaukos Corporation can grow by placing its current products into newer care pathways as minimally invasive ophthalmology gains wider use. With about 4 million U.S. cataract surgeries a year and glaucoma affecting over 80 million people worldwide, the bigger win is adoption timing, not new invention. If Glaukos Corporation captures more of these already moving procedures, it can outgrow the broader market, especially where cataract-linked glaucoma treatment is still underused.
Glaukos Expands MIGS Reach Across More Sites and Markets
In 2025, Glaukos Corporation's market development is selling the same MIGS and corneal products into more geographies and care sites, not changing the products. U.S. glaucoma still affects more than 3 million people, and global glaucoma tops 80 million, so the reachable patient pool is still wide.
Move beyond academic centers into community ophthalmology and ambulatory surgery centers, plus ex-U.S. markets, to widen access and reduce reliance on one reimbursement system.
| 2025 market cue | Value |
|---|---|
| U.S. glaucoma | >3 million |
| Global glaucoma | >80 million |
| U.S. cataract surgeries | ~4 million |
Get Your Copy
Glaukos Reference Sources
This Glaukos Amsoff Matrix Analysis preview is the same document customers receive after purchase – no sample, no filler, just the real report. It reflects the full structure, style, and content of the final file. After checkout, you unlock the complete version immediately.
Product Development
Commercialize the 36-month iDose TR implant
Glaukos Corporation's clearest product-development move is commercializing iDose TR, a sustained-release travoprost implant that delivers therapy for 36 months from one device. That matters because glaucoma care still depends on daily drops, and poor adherence is common; a long-acting implant can improve persistence and lower treatment drop-off.
It also gives physicians a middle path between eye drops and surgery, which can change sequencing in open-angle glaucoma and ocular hypertension. In 2025, Glaukos kept building around this platform as part of its broader glaucoma portfolio, using iDose TR to target a large chronic-treatment market where long-term control is the real value driver.
Advance next-generation corneal cross-linking
Advance next-generation corneal cross-linking fits product development because Glaukos Corporation is adding new corneal therapy to the same ophthalmology base that already buys MIGS. The corneal-health pipeline targets keratoconus, a disease that affects about 1 in 2,000 people, and it gives Glaukos Corporation a second clinical value driver beyond glaucoma. That matters because Glaukos Corporation reported $456.7 million in net sales in 2024, so broader corneal adoption can reduce reliance on one procedure family.
Refresh the iStent line with iterative upgrades
Glaukos Corporation can defend the iStent franchise by keeping the design moving, as it already spans iStent inject W and iStent infinite. The core point is simple: small implant gains can lift surgeon fit, confidence, and repeat use in a mature MIGS market where iStent remains a key brand. In 2025, that kind of iterative upgrade is still a practical way to protect share without waiting for rivals to reset the category.
Build a retinal-disease pipeline
Building a retinal-disease pipeline is product development because Glaukos Corporation is adding new therapies for the same eye-care customer base. It can use its ties with ophthalmologists and move into a second specialist group without leaving its core market. That would balance the portfolio across glaucoma, corneal health, and retinal disease, and Glaukos Corporation has already shown scale with 2025 revenue of about $400 million.
Combine devices with drug delivery
Glaukos Corporation is well placed to combine devices with drug delivery because its model already spans implants and pharmaceuticals, not just one mechanism.
That gives it room to design hybrid products like procedural devices plus sustained-release therapy, which can improve convenience and outcomes for patients.
It also raises the bar for rivals: pure-play device or drug firms must copy two regulated modalities, not one.
iDose TR Powers Glaukos' Next Growth Wave
Product development in Glaukos centers on iDose TR, a sustained-release travoprost implant that delivers therapy for 36 months from one device. In 2025, that long-acting model fits a market still burdened by poor drop adherence.
It also extends Glaukos beyond MIGS, with next-gen corneal cross-linking and retinal therapies adding new growth legs.
Iterating iStent inject W and iStent infinite helps protect share in mature glaucoma surgery.
| Asset | 2025 relevance |
|---|---|
| iDose TR | 36-month drug delivery |
| iStent line | Defense of MIGS share |
Diversification
Expand from 1 disease to 3 franchises
Glaukos Corporation has moved from one disease focus to three franchises: glaucoma, corneal health, and retinal disease. That cuts reliance on one diagnosis path, one reimbursement model, and one surgeon workflow. It also gives Glaukos Corporation more than one growth engine as iStent, iDose TR, and cornea and retina programs scale. In Amsoff terms, this is real diversification, not just line extension.
Blend 2 commercial models: device and pharma
Glaukos Corporation is no longer just a device maker; it now pairs implantable devices with sustained drug delivery, so it earns from two different commercial models. In FY2025, that mix widened its revenue base and lowered reliance on a single adoption curve, since devices and pharma differ on pricing, margin, and regulation. This dual engine can help Glaukos Corporation absorb shifts in procedure volumes or payer pressure better than a pure-device model.
Use Avedro-derived assets in corneal care
Glaukos Corporation's Avedro-derived assets moved it into corneal care, a different treatment logic from glaucoma and a clean diversification step. The platform came through acquisition, which let Glaukos Corporation enter a new clinical market without building from zero. Corneal cross-linking is FDA-approved for keratoconus and broadens Glaukos Corporation beyond pressure-lowering eye procedures.
Develop retina as a 2nd specialty channel
Glaukos Corporation's move into retina creates a second specialty channel beside glaucoma. Retina uses different physicians, procedures, and reimbursement economics, so the product mix and demand drivers are not tied to one core market. That lowers concentration risk and gives Glaukos Corporation more room for longer-horizon therapies and future launches.
Reduce reliance on 1 MIGS use case
Glaukos Corporation's broader portfolio reduces dependence on any one MIGS procedure or reimbursement path, which matters when payer rules, surgeon habits, or rival launches shift. That diversification can soften the impact if one category slows faster than expected and help support steadier 2025-2026 growth. In glaucoma, where adoption can move case by case, a wider mix of products gives Glaukos Corporation more resilience.
Glaukos Corporation's broader FY2025 mix lowers concentration risk
Glaukos Corporation's diversification in FY2025 spans glaucoma, corneal health, and retinal disease, so revenue is less tied to one surgeon workflow or reimbursement path. The shift from single-franchise devices to a mixed device-plus-drug model gives Glaukos Corporation more than one growth driver and lowers concentration risk.
| Area | FY2025 role | Why it matters |
|---|---|---|
| Glaucoma | Core franchise | Base demand |
| Corneal health | Avedro-led entry | New market |
| Retina | Expanding channel | More spread |
Frequently Asked Questions
Glaukos Corporation's main growth engine is still glaucoma, but it is now powered by 2 commercial platforms: MIGS and iDose TR. Those assets support growth across 3 disease areas, with the strongest near-term leverage coming from surgeon adoption, reimbursement, and durable drug delivery through 2026. The business mix is broader than it was 3 years ago.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.